sCD163 and sTARC are disease response biomarkers for Hodgkin's lymphoma
As published in Clinical Cancer Research,
combined sCD163 and sTARC are better markers of disease response in
patients with Hodgkin's lymphoma undergoing first-line therapy than either
marker alone. sCD163 reflected tumor burden during treatment, while
sTARC was more significant upon completion of therapy.
